Mirum to report Phase 3 EXPAND topline data for LIVMARLI in ultra-rare cholestatic liver diseases Oct. 12

• Mirum scheduled an investor call for Oct. 12, 2026 to present topline Phase 3 EXPAND results for LIVMARLI in ultra-rare cholestatic liver diseases.
• Data will cover treatment of cholestatic pruritus in patients aged 6 months or older, including biliary atresia.
• Results have not yet been presented; the company plans to disclose them during the call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261011330842) on October 11, 2026, and is solely responsible for the information contained therein.